DE60028544D1 - Prostata-spezifische gene zur diagnose, prognose und behandlung von prostata-krebs - Google Patents

Prostata-spezifische gene zur diagnose, prognose und behandlung von prostata-krebs

Info

Publication number
DE60028544D1
DE60028544D1 DE60028544T DE60028544T DE60028544D1 DE 60028544 D1 DE60028544 D1 DE 60028544D1 DE 60028544 T DE60028544 T DE 60028544T DE 60028544 T DE60028544 T DE 60028544T DE 60028544 D1 DE60028544 D1 DE 60028544D1
Authority
DE
Germany
Prior art keywords
prostate cancer
prostate
diagnosis
treatment
forecast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60028544T
Other languages
English (en)
Other versions
DE60028544T2 (de
Inventor
Gang An
Robert Veltri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratory Corp of America Holdings
Original Assignee
Laboratory Corp of America Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratory Corp of America Holdings filed Critical Laboratory Corp of America Holdings
Publication of DE60028544D1 publication Critical patent/DE60028544D1/de
Application granted granted Critical
Publication of DE60028544T2 publication Critical patent/DE60028544T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57434Specifically defined cancers of prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/85Reproductive organs or embryos
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
DE60028544T 1999-02-09 2000-01-24 Prostata-spezifische gene zur diagnose, prognose und behandlung von prostata-krebs Expired - Lifetime DE60028544T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US247188 1994-05-20
US09/247,188 US6156515A (en) 1999-02-09 1999-02-09 Prostate-specific gene for diagnosis, prognosis and management of prostate cancer
PCT/US2000/002052 WO2000047773A1 (en) 1999-02-09 2000-01-24 A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer

Publications (2)

Publication Number Publication Date
DE60028544D1 true DE60028544D1 (de) 2006-07-20
DE60028544T2 DE60028544T2 (de) 2007-06-06

Family

ID=22933947

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60028544T Expired - Lifetime DE60028544T2 (de) 1999-02-09 2000-01-24 Prostata-spezifische gene zur diagnose, prognose und behandlung von prostata-krebs

Country Status (8)

Country Link
US (6) US6156515A (de)
EP (2) EP1151140B9 (de)
AT (1) ATE329057T1 (de)
AU (1) AU2740100A (de)
CA (1) CA2362527C (de)
DE (1) DE60028544T2 (de)
ES (1) ES2394093T3 (de)
WO (1) WO2000047773A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156515A (en) 1999-02-09 2000-12-05 Urocor, Inc. Prostate-specific gene for diagnosis, prognosis and management of prostate cancer
GB9912965D0 (en) * 1999-06-03 1999-08-04 Oxford Biomedica Ltd In vivo selection method
WO2002042776A2 (en) * 2000-11-01 2002-05-30 Diadexus, Inc. Compositions and methods relating to prostate specific genes and proteins
AU2002236579A1 (en) * 2000-11-06 2002-05-21 Diadexus, Inc. Compositions and methods relating to prostate specific genes and proteins
WO2002038810A2 (en) * 2000-11-06 2002-05-16 Diadexus, Inc. Compositions and methods relating to prostate specific genes and proteins
WO2002042463A2 (en) * 2000-11-21 2002-05-30 Diadexus, Inc. Compositions and methods relating to prostate specific genes and proteins
GB0119852D0 (en) * 2001-08-15 2001-10-10 Univ York Baculovirus
WO2003023355A2 (en) * 2001-09-06 2003-03-20 The Burnham Institute Serine/threonine hydrolase proteins and screening assays
BR0213520A (pt) * 2001-10-26 2006-05-23 Immunivest Corp método para diagnosticar a gravidade de uma doença em um indivìduo de teste, e, kit de teste para triagem de uma amostra de paciente quanto à presença de células cancerosas circulantes
AU2002364202A1 (en) * 2001-12-21 2003-07-30 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Novel metastasis suppressor gene on human chromosome 8
US7534580B2 (en) * 2002-05-01 2009-05-19 Ambrilia Biopharma Inc. PSP94 diagnostic reagents and assays
US7713693B1 (en) 2004-09-01 2010-05-11 University Of Louisiana At Monroe Human cancer cell specific gene transcript
US20070029205A1 (en) * 2005-08-08 2007-02-08 Shoou-Aaey Chen Method of surface treatment for metal and nonmetal surfaces
CA2680556A1 (en) * 2007-03-12 2008-09-18 Miraculins Inc. Biomarkers of prostate cancer and uses thereof
US20100294681A1 (en) * 2007-06-05 2010-11-25 Dylina Tim J Golf bag
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
WO2013112528A1 (en) * 2012-01-23 2013-08-01 West Chester University Of Pennsylvania Methods and compositions relating to proliferative disorders of the prostate
US9977033B2 (en) 2012-09-11 2018-05-22 The Board Of Regents Of The University Of Texas System Methods for assessing cancer recurrence

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) * 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) * 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4277437A (en) * 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4215051A (en) * 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4366241A (en) * 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4883750A (en) * 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1987000880A1 (en) * 1985-08-09 1987-02-12 Soederstroem Gert Safety device
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
AU622104B2 (en) * 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
IL86724A (en) * 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
WO1989001025A2 (fr) * 1987-07-24 1989-02-09 Allrutan Bio-Produkte Gmbh Produits alimentaires, produits alimentaires dietetiques, additifs alimentaires, produits cosmetiques et medicaments a base de levure
AU622426B2 (en) * 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
AU624601B2 (en) * 1988-01-21 1992-06-18 Genentech Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) * 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US4932207A (en) * 1988-12-28 1990-06-12 Sundstrand Corporation Segmented seal plate for a turbine engine
WO1992010591A1 (en) * 1990-12-14 1992-06-25 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5262311A (en) * 1992-03-11 1993-11-16 Dana-Farber Cancer Institute, Inc. Methods to clone polyA mRNA
ATE231920T1 (de) * 1992-03-11 2003-02-15 Dana Farber Cancer Inst Inc Methode um mrna zu klonieren
CA2148350A1 (en) * 1992-10-29 1994-05-11 Carlo Croce Methods of detecting micrometastasis of prostate cancer
US5279721A (en) * 1993-04-22 1994-01-18 Peter Schmid Apparatus and method for an automated electrophoresis system
US5639656A (en) * 1994-03-31 1997-06-17 Medical College Of Hampton Road Antibodies reactive with biological markers of benign prostate hyperplasia
US5658730A (en) * 1994-12-23 1997-08-19 Ctrc Research Foundation Methods of human prostate cancer diagnosis
JPH10513044A (ja) * 1995-01-20 1998-12-15 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒト前立腺特異的還元酵素
US5633161A (en) * 1995-03-29 1997-05-27 Millennium Pharmaceuticals, Inc. Murine gene fomy030 coding for tumor progression inhibitor
US5882864A (en) * 1995-07-31 1999-03-16 Urocor Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en) * 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
WO1999037811A1 (en) * 1998-01-21 1999-07-29 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6476207B1 (en) * 1998-06-11 2002-11-05 Chiron Corporation Genes and gene expression products that are differentially regulated in prostate cancer
US6156515A (en) 1999-02-09 2000-12-05 Urocor, Inc. Prostate-specific gene for diagnosis, prognosis and management of prostate cancer
US8067152B2 (en) * 2006-02-27 2011-11-29 The Fred Hutchinson Cancer Research Center Liver cancer biomarkers
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Also Published As

Publication number Publication date
EP1734134B1 (de) 2012-08-29
US20030017472A1 (en) 2003-01-23
ES2394093T3 (es) 2013-01-17
US20020068281A1 (en) 2002-06-06
US6369195B1 (en) 2002-04-09
US20080044416A1 (en) 2008-02-21
US20110286917A1 (en) 2011-11-24
EP1151140A1 (de) 2001-11-07
US7993830B2 (en) 2011-08-09
CA2362527C (en) 2011-07-12
ATE329057T1 (de) 2006-06-15
EP1151140A4 (de) 2002-12-18
EP1151140B9 (de) 2007-01-10
EP1151140B1 (de) 2006-06-07
CA2362527A1 (en) 2000-08-17
WO2000047773A1 (en) 2000-08-17
EP1734134A3 (de) 2007-03-14
AU2740100A (en) 2000-08-29
EP1734134A2 (de) 2006-12-20
US6156515A (en) 2000-12-05
DE60028544T2 (de) 2007-06-06

Similar Documents

Publication Publication Date Title
DE60028544D1 (de) Prostata-spezifische gene zur diagnose, prognose und behandlung von prostata-krebs
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
WO2002029086A3 (en) Nucleic acid sequences differentially expressed in cancer tissue
DE69510810D1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
NO972006D0 (no) Ny metode for diagnose av sykdommer
IS7173A (is) Líffræðilegar afurðir
WO2004110345A8 (en) Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
DK1218509T3 (da) Fibroblast vækstfaktorlignende polypeptider
ATE426043T1 (de) Verfahren zur identifizierung des brustkrebsrisikos
DK1536006T3 (da) Cancerantigener og anvendelse deraf
ATE328077T1 (de) Gen assoziiert mit iga glomerulonephritis
WO1999018210A3 (en) Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
EP1277843A3 (de) Neue humane Gene und Genexpressionsprodukte die in Zusammenhang mit Darmkrebs stehen
ATE321135T1 (de) Verfahren zur diagnose und behandlung neurologischer erkrankungen
ATE334145T1 (de) Neues menschliches ulip/crmp protein und seine verwendung zur diagnose zur behandlung von krebs und von neurologischen paraneoplastischen syndromen
DE60018964D1 (de) Diagnose und behandlung von krebs unter verwendung von sgp28-ähnlichen molekülen
DE60029939D1 (de) Diagnosisverfahren für whipples krankheit
ATE430806T1 (de) (-)-strang rns virusvektor für nervenzellen
WO2004048548A3 (en) Methods for identifying risk of breast cancer and treatments thereof
ATE420210T1 (de) Diagnose des brustkrebsrisikos
DE60212861D1 (de) Verfahren zur Diagnose von Fettsucht
ATE378352T1 (de) Eine nukleinsäure, die in menschlichen tumorzellen aufreguliert wird, ein von dieser kodiertes protein und ein verfahren zur tumordiagnose
MX9707259A (es) Homologos de celubrevinas.
MX9707852A (es) Homologo de fosfolipasa c.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition